Recently presented study data shows that low-to-intermediate risk prostate cancer patients who received low-dose permanent brachytherapy had excellent long-term outcomes. Read the original article here: “Low-dose Brachytherapy Seen as Viable Choice for Lower Risk Patients, Long-term Study Finds”

The nine-year follow-up results showed only a small minority of the patients, 11-14%, treated with either Iodine-125 (I-125) or Cesium-131 (Cs-131) brachytherapy saw their cancer return.  The August 2017, Int J Rad Oncol Bio Phys paper- “Long-term PSA Outcomes in a Single Institution, Prospective Randomized Cesium-131/Iodine-125 Permanent Prostate Brachytherapy Trial” was presented at this year’s American Society for Radiation Oncology (ASTRO) 2017 Annual Conference in San Diego, California.  The study consisted of 140 patients with a median follow-up of 95 months.  Study treatment efficacy was measured through biochemical relapse rates, defined as a rise in PSA levels.